CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.68
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.85

23 Feb
2024

0.000

OPEN

$1.85

0.000

HIGH

$1.86

21,013

LOW

$1.85

TARGET
$3.80 105.4% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx - 7.2 - 7.2 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A 0.0% xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.54

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-7.2
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx23.2 M
Book Value Per Share xxxxxxxxxxxxxxx39.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.7 M
Net Profit Margin xxxxxxxxxxxxxxx-28.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-16.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.02 %
Return on Assets xxxxxxxxxxxxxxx-12.56 %
Return on Equity xxxxxxxxxxxxxxx-16.61 %
Return on Total Capital xxxxxxxxxxxxxxx-16.46 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx2.98

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx1.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.67 %
Cost of Goods Sold xxxxxxxxxxxxxxx17 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

07/02/2024

1

Buy

$3.80

105.41%

According to a trading update from Cyclopharm, revenues fell by -$2.5m in the second half of 2023. The company disclosed full year unaudited revenues of $28.9m, a modest miss to Bell Potter's $29.7m forecast, implying second half revenues of $13.2m.

Bell Potter explains the first half did benefit from large fees from third party logistics contracts, and while these are not one off they can differ from period to period.

The Technegas rollout continues, with eighty contracts issued, six of which are either executed or in final stages.

The broker anticipates a full year earnings loss of -$6m. The Buy rating is retained and the target price decreases to $3.80 from $4.25.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 1.00 cents and EPS of minus -7.20 cents.
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of minus -2.50 cents.

CYC STOCK CHART